Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.
The Pharma Letter5h
FDA accelerated approval for Novartis’ Vanrafia
Swiss pharma giant Novartis (NOVN: VX) today announced the US Food and Drug Administration (FDA) has granted accelerated ...
Medical Dialogues6h
Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy
Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent ...
The Financial Express11h
Novartis gets USFDA nod for its therapy to treat Berger’s disease
IgAN is a progressive, rare kidney disease in which the immune system attacks the kidneys, often causing glomerular inflammation and proteinuria.
Sportschosun on MSN16h
Diabetes Stabilizes Kidney Function After Nephrology Treatment
Comparison of eGFR change rates before and after renal internal medical referral. Before the referral (left orange), the ...
Medscape3h
SGLT2 Inhibitors Progressing to New Standard After TAVI
In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...
The American Journal of Managed Care52m
FDA Approves Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy
Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...
FMIBlog13h
Global Cardiometabolic Drugs Market to Exceed USD 70 Billion by 2032 Amid Rising Demand for Novel Therapies | FMI
The global cardiometabolic drugs market is poised for significant expansion, with market size reaching USD 50 billion in 2021 and expected to surpass USD 70 billion by 2032. The market is projected to ...